Loading
A phase 1/2 trial of Gedatolisib, Darolutamide in prostate cancer, run by Celcuity Inc, now recruiting.
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer is a phase 1/2 interventional study registered as NCT06190899 by Celcuity Inc, with 54 participants planned, started 2024-01-01 and due to reach its primary completion in 2028-01. Interventions recorded: Gedatolisib, Darolutamide. Conditions listed: mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Celcuity, Gedatolisib, Small-molecule kinase inhibitors.
Shares Celcuity, Gedatolisib, Small-molecule kinase inhibitors.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/